Role of nigral NFκB p50 and p65 subunit expression in haloperidol-induced neurotoxicity and stereotyped behavior in rats

European Neuropsychopharmacology

Volumn 16, Issue 7, 2006, Pages 491-497

  Saldana M ^a   Bonastre, M ^a   Aguilar, E ^a   Marin, C ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Clozapine; Haloperidol; Neurotoxicity; NF b; Stereotypies

Indexed keywords

APOMORPHINE; BRAIN PROTEIN; CLOZAPINE; DOPAMINE TRANSPORTER; HALOPERIDOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUROLEPTIC AGENT; PROTEIN P50; PROTEIN SUBUNIT; SODIUM CHLORIDE; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CHRONIC TOXICITY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; EXPERIMENTAL MODEL; LONG TERM EXPOSURE; MALE; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; STEREOTYPY; TARDIVE DYSKINESIA; WESTERN BLOTTING; ANIMAL; ANIMAL BEHAVIOR; COMPARATIVE STUDY; DRUG EFFECT; GENE EXPRESSION; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA; TOXICITY AND INTOXICATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; CLOZAPINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENE EXPRESSION; HALOPERIDOL; MALE; NEUROTOXICITY SYNDROMES; NF-KAPPA B P52 SUBUNIT; RATS; RATS, SPRAGUE-DAWLEY; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA; TRANSCRIPTION FACTOR RELA;

EID: 33748157826     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.01.001     Document Type: Article

References (72)

1. Acarin L., Gonzalez B., and Castellano B. STAT3 and NFκB activation precedes glial activity in the excitotoxically injured young cortex but not in the corresponding distal thalamic nuclei. J. Neuropathol. Exp. Neurol. 59 (2000) 151-1633
2. Allard P., Eriksson K., Ross S.B., and Marcusson J.O. Unaltered [3-H]-GBR-12935 binding after chronic treatment with dopamine active drugs. Psychopharmacology 102 (1990) 291-294
3. Andreassen O.A., and Jorgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rat. Implications for tardive dyskinesia?. Prog. Neurobiol. 61 (2000) 525-541
4. Andreassen O.A., Aamo T.O., and Jorgensen H.A. Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. Br. J. Pharmacol. 119 (1996) 751-757
5. Andreassen O.A., Ferrante R.J., Aamo T.O., Beal M.F., and Jorgensen H.A. Oral dyskinesias and histopathological alterations in substantia nigral after long-term haloperidol treatment of old rats. Neuroscience 122 (2003) 717-725
6. Ase A.R., Amdiss F., Herbert C., Huang N., Van Gelder N.M., and Reader T.A. Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin 1 A receptors. J. Neural Transm. 106 (1999) 75-105
7. Bauer R., Mayr A., Lederer W., Needham P.L., Kilpatrick I.C., Fleischhacker W.W., and Marksteiner J. Further evidence that behavioral tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antispychotic drugs. Neuropsychopharmacology 23 (2000) 46-55
8. Beg A.a., Sha W.C., Bronson R.T., Ghosh S., and Baltimore D. Embryonic lethality and liver degeneration in mice lacking the Rel A component of NF-kappa B. Nature 376 (1995) 167-170
9. Beg A.A., and Baltimore D. An essential role for NFκB in preventing TNF-α induced cell death. Science 274 (1996) 782-784
10. Bloomquist J., King E., Wright A., Mytilineou C., Kimura K., and Castagnoli Jr. N. 1-methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J. Pharmacol. Exp. Ther. 270 (1994) 822-830
11. Bubser M., and Deutch A.Y. Differential effects of typical and atypical antipsychotic drugs on striosome and matrix compartments of the striatum. Eur. J. Neurosci. 15 (2002) 713-720
12. Buckhardt C., Kelly J.P., Lim Y.H., Filley C.M., and Parker Jr. W.D. Neuroleptic medications inhibit complex I of the electron transport chain. Ann. Neurol. 33 (1993) 512-517
13. Burt D.R., Creese I., and Snyder S.H. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196 (1977) 326-328
14. Cadet J.L., and Kahler L.A. Free radicals mechanisms in schizophrenia and tardive dyskinesia. Neurosci. Biobehav. Rev. 18 (1994) 457-467
15. Casey D.E. Tardive dyskinesia: pathophysiology. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth generation of Progress (1995), Raven, New York 1497-1502
16. Casey D.E. Tardive dyskinesia: pathophysiology and animal models. J. Clin. Psychiatry 61 (2000) 5-9
17. Coyle J.T., and Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262 (1993) 689-695
18. Cottingham S.L., Pickar D., Shimotake T.K., Montpied P., Paul S.M., and Crawley J.N. Tyrosine hydroxylase and cholecystokinin mRNA levels in the substantia nigra, ventral tegmental area, and locus coeruleus are unaffected by acute and chronic haloperidol administration. Cell. Mol. Neurobiol. 10 (1990) 41-50
19. Ellison G., and See R.E. Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia. Psychopharmacology 98 (1989) 564-566
20. Ernst A.M. Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacologia 10 (1967) 316-323
21. Felszeghy K., Banisadr G., Rostene W., Nyakas C., and Haour F. Dexamethasone downregulate chemokine receptor CXCR4 and exerts neuroprotection against hypoxia/ischemia-induced brain injury in neonatal rats. Neuroimmunomodulation 11 (2004) 404-413
22. Fibiger H.C., and Lloyd K.G. Neurobiological susbtrates of tardive dyskinesias: the GABA hypothesis. Trends Neurosci. 7 (1984) 462-464
23. Fray P.J., Sahakian B.J., Robbins T.W., Koob G.F., and Iversen S.D. An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine. Psychopharmacology 69 (1980) 253-259
24. Gabriel C., Justicia C., Camins A., and Planas A. Activation of nuclear factor κB in the rat brain after transient focal ischemia. Mol. Brain Res. 65 (1999) 61-69
25. Gale K. Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in subtantia nigra. Nature 283 (1980) 569-570
26. Galili-Mosberg R., Gil-Ad I., Weizman A., Melamed E., and Often D. Haloperidol-induced meurotoxicity-possible implications for tardive dyskinesia. J. Neural Transm. 107 (2000) 479-490
27. Glazer G.W., Camandola S., and Mattson M.P. NF-κB mediates the cell survival-promoting action of an activity-dependent neurotrophic factor peptide. J. Neurochem. 75 (2000) 101-108
28. Golde S., Coles A., Lindquist J.A., and Compston A. Decreased iNOS synthesis mediates dexamethasone-induced protection of neurons from inflammatory injury in vitro. Eur. J. Neurosci. 18 (2003) 2527-2537
29. Ikeda H., Adachi K., Hasegawa M., Sato M., Hirose N., Koshikawa N., and Cools A.R. Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia. J. Neural Transm. 106 (1999) 1205-1216
30. Kane J.M. Tardive dyskinesia: epidemiology and clinical presentation. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress vol. 39 (1995), Raven Press, New York 1485-1495
31. Kassed C.A., Willing A.E., Garbuzova-Davis S., Sanberg P.R., and Pennypacker K.R. Lack of NF-κB exacerbates degeneration of hippocampal neurons after chemical exposure and impairs learning. Exp. Neurol. 176 (2002) 277-288
32. Kitaoka Y., Kumai T., Kitaoka Y., Lam T.T., Munemasa Y., Isenoumi K., Motoki M., Kuribayashi K., Kogo J., Kobayashi S., and Ueno S. Nuclear factor-kappa B p65 in NMDA-induced retinal neurotoxicity. Mol. Brain Res. 131 (2004) 8-16
33. Klawans H., and Rubovits R. An experimental model of tardive dyskinesia. J. Neural Transm. 33 (1972) 235-246
34. LaHoste G.J., and Marshall J.F. Dopamine supersensitivity and D-1/D-2 synergism are unrelated to changes in striatal receptor density. Synapse 12 (1992) 14-26
35. LaHoste G.J., Yu J., and Marshall J.F. Striatal fos expression is indicative of dopamine D-1/D-2 synergism and receptor supersensitivity. Proc. Nat. Acad. Sci. U. S. A. 90 (1993) 7451-7455
36. Lerner P., Nose P., Gordon E.K., and Lovenberg W. Haloperidol: effect of long-term treatment on rat striatal dopamine synthesis and turnover. Science 197 (1977) 181-183
37. Levinson A.J., Garside S., Rosebush P.I., and Mazurek M.F. Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in susbtantia nigra but not ventral tegmental area in the rat. Neuroscience 84 (1998) 201-211
38. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
39. Marchese G., Casu M.A., Bartholini F., Ruiu S., Saba P., Gessa G.L., and Pani L. Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigrostriatal dopaminergic neurons directly related to "early onset" vacuous chewing. Eur. J. Neurosci. 15 (2002) 1187-1196
40. Marchese G., Bartholini F., Ruiu S., Casti P., Casu G.L., and Pani L. Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylase-immunostaining alterations induced by haloperidol. Eur. J. Pharmacol. 483 (2004) 65-69
41. Marin C., and Chase T.N. D-1 but not D-2 dopamine stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor upregulation. Eur. J. Pharmacol. 231 (1993) 191-196
42. Marin C., Parashos S.A., Kapitzoglou-Logothetis V., Peppe A., and Chase T.N. D-1 and D-2 dopamine receptor-mediated mechanisms and behavioral supersensitivity. Pharmacol. Biochem. Behav. 45 (1993) 195-200
43. Marin C., Engber T.M., Bonastre M., Chase T.N., and Tolosa E. Effect of long-term haloperidol treatment on striatal neuropeptides: relation to stereotyped behavior. Brain Res. 731 (1996) 57-62
44. Marin C., Bonastre M., and Tolosa E. Striatal c-fos levels do not correlate with haloperidol-induced behavioral supersensitivity. Synapse 23 (1996) 89-93
45. Mattson M.P., Culmsee C., Yu Z., and Camandola S. Roles of nuclear factor κB in neuronal survival and plasticity. J. Neurochem. 74 (2000) 443-456
46. Mazurek M.F., Savedia S.M., Bobba R.S., Garside S., and Rosebush P.I. Persistent loss of tyrosine hydroxyalse immunoreactivity in the substantia nigra after neuroleptic withdrawal. J. Neurol. Neurosurg. Psychiatry 64 (1998) 799-801
47. Meshul C.K., Janowsky A., Casey D.E., Stalbaumer R.K., and Taylor B. Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus accumbens and medial prefrontal cortex. Psychopharmacology 106 (1992) 45-52
48. Meshul C.K., Stallbaumer R.K., Taylor B., and Janowsky A. Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res. 648 (1994) 181-195
49. Morgenstern H., and Glazer W.M. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia study. Arch. Gen. Psychiatry 50 (1993) 723-733
50. Nakai M., Qin Z.H., Chen J.F., Wang Y., and Chase T.N. Kainic acid-induced apoptosis in rat striatum is associated with nuclear factor-κB activation. J. Neurochem. 74 (2000) 647-658
51. Parsons B., Togasaki D.M., Kassir S., and Przedborski S. Neuroleptics up-regulate adenosine A2A receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. J. Neurochem. 65 (1995) 2057-2064
52. Peacock L., and Gerlach J.A. Reanalysis of the dopamine theory of tardive dyskinesia the hypothesis of dopamine D1/D2 imbalance. In: Yassa R., Nair N.P.V., and Jeste D.V. (Eds). Neuroleptic-Induced Movement Disorders (1997), Cambridge University Press, New York 141-160
53. Perez-Otano I., McMilian M.K., Chen J., Bing G., Hong J.S., and Pennypacker K.R. Induction of NF-κB-like transcription factors in brain areas susceptible to kainate toxicity. Glia 16 (1996) 306-315
54. Post A., Holsboer F., and Behl C. Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-kappa B and neuroprotection by antioxidants. J. Neurosci. 18 (1998) 8236-8246
55. Qin Z.H., Wang Y., Nakai M., and Chase T.N. Nuclear factor-κB contributes to excitotoxin-induced apoptosis in rat striatum. Mol. Pharmacol. 53 (1998) 33-42
56. Rivest R., Falardeu P., and DiPaolo T. Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res. 692 (1995) 269-272
57. Rollema H., Skolnik M., D'Engelbronner J., Igarashi K., Usuki E., and Castagnoli Jr. N. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J. Pharmacol. Exp. Ther. 268 (1994) 380-387
58. Rosengarten H., Schweitzer J.W., and Friedhoff A.J. Possible genetic factors underlying the pathophysiology of tardive dyskinesia. Pharmacol. Biochem. Behav. 49 (1994) 663-667
59. See R.E., and Lynch A.M. Chronic haloperidol potentiates stimulated glutamate release in caudate putamen, but not prefrontal cortex. Neuroreport 6 (1995) 1795-1798
60. See R.E., Lynch A.M., Aravagiri M., Aravagiri C.B., and Owens M.J. Chronic haloperidol-induced changes in regional dopamine release and metabolism and neurotensin content in rats. Brain Res. 704 (1995) 202-209
61. Sen R., and Baltimore D. Inductibility of k immunoglobulin enhancer-binding protein NFκB by a posttranslational mechanism. Cell 47 (1986) 921-928
62. Simpson C.S., and Morris B.J. Activation of nuclear factor-κB by nitric oxide in rat striatal neurones: differential inhibition of the p50 and p65 subunits by dexamethasone. J. Neurochem. 73 (1999) 353-361
63. Steen V.M., Lovlie R., MacEwan T., and McCreadie R.G. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol. Psychiatry 2 (1997) 139-145
64. Tarsy D., and Baldessarini R. Behavioral hypersensitivity to apomorphine following chronic treatment with drugs which interfere with synaptic function of catecholamines. Neuropharmacology 13 (1974) 927-940
65. Tsai G.C., and Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 165-179
66. Turrone P., Remington G., Kapur S., and Nóbrega J.N. Differential effects of within-day continuous vs transient dopamine D-2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology 28 (2003) 1433-1439
67. Waddington J.L. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology 101 (1990) 431-447
68. Waddington J.L. Rodent and other animal models of tardive dyskinesia during long-term neuroleptic drug administration. Controversies and implications for the clinical syndrome. In: Yassa R., Nair N.P.V., and Jeste D.V. (Eds). Neuroleptic-Induced Movements Disorders (1997), Cambridge University Press, New York 225-237
69. Weinhold P., Wegner J.T., and Kane J.M. Familial occurrence of tardive dyskinesia. J. Clin. Psychiatry 42 (1981) 162-165
70. Yang J.T., Lee T.H., Weng H.H., Chang C.N., Chen W.C., Cheng W.C., and Wu J.H. Dexamethasone enhances NT-3 expression in rat hippocampus after traumatic brain injury. Exp. Neurol. 192 (2005) 437-443
71. Yokoyama H., Kasai N., Ueda Y., Niwa R., Konaka R., Mori N., Tsuchihashi N., Matsue T., Ohya-Nishiguchi H., and Kamada H. In vivo analysis of hydrogen peroxide and lipid radicals in the striatum of rats under long-term administration of a neuroleptic. Free Radic. Biol. Med. 24 (1998) 1056-1060
72. Yu Z., Zhou D., Bruce-Keller A.J., Kindy M.S., and Mattson M.P. Lack of the p50 subunit of nuclear factor-κB increases the vulnerability of hippocampal neurons to excitotoxic injury. J. Neurosci. 19 (1999) 8856-8865